CVRx to Report Third Quarter 2022 Financial and Operating Results and Host Conference Call on November 1st, 2022

Rhea-AI Summary

CVRx, a medical device company, will release its third quarter 2022 financial results on November 1, 2022, after market close. A conference call to discuss these results is scheduled for 5:30 p.m. Eastern Time on the same day and will be available via webcast. CVRx focuses on innovative neuromodulation solutions, including Barostim™, the first FDA-approved device for heart failure treatment, which uses electrical pulses to enhance baroreflex and autonomic nervous system balance. Barostim has also received CE Mark approval in Europe.

MINNEAPOLIS, Oct. 18, 2022 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that it plans to release third quarter 2022 financial and operating results after market close on Tuesday, November 1st, 2022. The Company will host a conference call to review its results at 5:30 p.m. Eastern Time the same day.

The conference call will be broadcast live in listen-only mode via webcast at https://edge.media-server.com/mmc/p/8kfcmjvb. To listen to the conference call on your telephone, participants may register for the call here. While it is not required, it is recommended you join 10 minutes prior to the event start.

About CVRx, Inc.

CVRx is focused on the development and commercialization of Barostim™, the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of patients with heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. Baroreceptors activate the body’s baroreflex, which in turn triggers an autonomic response to the heart. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure. Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S. It has also received the CE Mark for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit www.cvrx.com.

Investor Contact:
Mark Klausner or Mike Vallie
ICR Westwicke
443-213-0501
ir@cvrx.com

Media Contact:
Erich Sandoval
Finn Partners
212-867-1762
erich.sandoval@finnpartners.com

FAQ

What date will CVRx release its third quarter 2022 results?

CVRx will release its third quarter 2022 financial results on November 1, 2022.

What time is the CVRx conference call scheduled for?

The conference call for CVRx's third quarter 2022 results is scheduled for 5:30 p.m. Eastern Time on November 1, 2022.

How can I listen to the CVRx conference call?

You can listen to the CVRx conference call via webcast or by phone after registering for the call.

What is Barostim from CVRx?

Barostim is an implantable device developed by CVRx to treat heart failure using neuromodulation.

What approvals has Barostim received?

Barostim is FDA-approved for heart failure treatment in the U.S. and has received CE Mark approval in Europe.